Cointime update: Novo Nordisk’s clinical trial shows that its Wegovy injection reduces BMI and obesity prevalence in children. The trial results indicate the weight-loss drug is effective in a pediatric population, lowering both body mass index and the rate of obesity among young participants. The finding extends the company’s obesity franchise into younger patients.
Novo Nordisk Trial Shows Wegovy Injection Cuts Children’s BMI and Obesity Prevalence
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
3m ago
Dollar Holds Near 19-Month High on Fed Rate Hike Expectations
2h ago
Iran military says it struck US drone and missile facilities at Kuwait’s Ali Al Salem base
2h ago
MARA Sells 1,713.9 BTC for $121M; BOJ Signals More Rate Hikes
3h ago
BOJ’s Ueda Says Rate Hikes Should Continue to Anchor Inflation
4h ago
South Korea’s KOSPI Turns Negative After Earlier Gaining Over 3%
4h ago
Spot silver falls 2.00% intraday to $46.44/oz, lowest since Sept 29, 2025